Jean-François Magny
Necker-Enfants Malades Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jean-François Magny.
Heart | 2012
Babak Khoshnood; Nathalie Lelong; Lucile Houyel; Anne-Claire Thieulin; Jean-Marie Jouannic; Suzel Magnier; Anne-Lise Delezoide; Jean-François Magny; Caroline Rambaud; Damien Bonnet; François Goffinet
Objective To assess the prevalence, timing of diagnosis and infant mortality of congenital heart defects (CHD) with population-based data and using a classification that allows regrouping of the International Paediatric and Congenital Cardiac Code into a manageable number of categories based on anatomic and clinical criteria (ACC-CHD). Design Population-based cohort study. Setting Greater Paris. Patients All cases (live births, terminations of pregnancy for foetal anomaly (TOPFA), foetal deaths) diagnosed prenatally, or up to 1 year of age in the birth cohorts, May 2005–April 2008, for women in Greater Paris (n=317 538 births). Diagnoses were confirmed in specialised centres and subsequently coded and classified into the categories of ACC-CHD by paediatric cardiologists in the study group. Results The total number of CHD was 2867, including 2348 live births (82%), 466 TOPFA (16.2%) and 53 foetal deaths (1.8%). The total prevalence of CHD was 90 per 10 000. After exclusion of ventricular septal defects (VSD), 40% of ‘isolated’ CHD was diagnosed prenatally with about one half of the remaining diagnosed before 7 days of age. Nevertheless, one in five cases of these major CHD was diagnosed after the fourth week. Infant mortality of ‘isolated’ CHD-VSD excluded was 8.5% with 40% of deaths occurring after the fourth week of life. These outcomes varied substantially across categories of ACC-CHD. Conclusions Timing of diagnosis, TOPFA, risk and timing of infant mortality were highly variable across the categories of CHD in ACC-CHD, suggesting that it may be a useful measure of severity, and hence, predictor of outcomes of CHD.
Clinical Infectious Diseases | 2011
Marianne Leruez-Ville; Christelle Vauloup-Fellous; Sophie Couderc; Sophie Parat; Christine Castel; Véronique Avettand-Fenoel; Tiffany Guilleminot; Liliane Grangeot-Keros; Yves Ville; Sophie Grabar; Jean-François Magny
BACKGROUND Congenital cytomegalovirus (CMV) infection is a public health issue, and implementation of neonatal screening has been debated. Detection of CMV DNA by polymerase chain reaction (PCR) of dried blood spots (DBS) routinely collected for metabolic screening from all newborns has been proposed for congenital CMV infection screening. The goal of this study was to prospectively assess the performance of 2 CMV PCR assays of DBS for CMV neonatal screening in a selected population of neonates. METHODS We studied prospective congenital CMV screening in a population of neonates either born with symptoms compatible with congenital CMV or born to mothers with a history of primary infection during pregnancy. For each neonate, 2 CMV PCR assays of DBS were blindly performed in parallel with a gold standard technique (ie, CMV PCR of a urine sample). RESULTS Two hundred seventy-one neonates were studied, and CMV infection, defined by a positive urine sample in the first week of life, was confirmed in 64 (23.6%). Nineteen infected (29.7%) neonates were symptomatic, and 45 (70.3%) were asymptomatic. The ranges of sensitivity, specificity, positive predictive value, and negative predictive value for the 2 CMV PCR assays of DBS were 95.0%-100%; 98.1%-99.0%; 94.1%-96.9%, and 98.5%-100%, respectively. CONCLUSIONS The sensitivity and specificity of both CMV PCR assays of DBS to identify congenital CMV were very high in this population of neonates with a high risk of sequelae. These new data should be considered in the ongoing debate on the appropriateness of the use of DBS as a sample to screen for congenital CMV infection.
Archives of Cardiovascular Diseases | 2013
Daniela Laux; Bettina Bessières; Lucile Houyel; Maryse Bonnière; Jean-François Magny; Fanny Bajolle; Younes Boudjemline; Damien Bonnet
BACKGROUND Congenital left coronary artery abnormalities such as ostial stenosis or atresia are extremely rare. Diagnosis in the neonate has not been reported. AIMS To describe five neonates with left coronary artery orifice abnormalities and discuss pathophysiology, diagnosis and treatment options, with a focus on the importance of autopsy in unexpected neonatal death. METHODS Retrospective assessment of medical files of neonates with left coronary abnormalities seen during a 12-year period (2000-2012). RESULTS Three neonates with anatomical (n=2) and functional (n=1) left coronary stenosis and two neonates with ostial atresia were identified. The three infants with coronary stenosis died within minutes to days after birth because of cardiac failure refractory to intensive care treatment; at autopsy, left coronary ostial stenosis (n=2) and high take-off with acute angle origin and tangential vertical course (n=1) were diagnosed. The fourth neonate was in cardiac failure due to critical aortic stenosis; left coronary ostial atresia was diagnosed during an emergency catheter procedure and the infant died after aortic valve dilatation. The fifth infant had a cardiac arrest on the third day of life; she was diagnosed with left coronary ostial atresia by coronary angiography and died during attempted revascularization surgery at 2 weeks of life. CONCLUSION Congenital coronary ostial abnormalities can lead to severe heart failure and unexpected neonatal death. Systematic examination of the coronary arteries should be part of any neonatal autopsy. Coronary angiography remains the diagnostic method of choice despite advances in non-invasive imaging. Revascularization surgery seems indicated in symptomatic children based on small patient series.
Retrovirology | 2009
Marianne Leruez-Ville; Christelle Vauloup-Fellous; Sophie Couderc; Sophie Parat; Salima Oucherif; Jean-François Magny
Address: 1Hopital Necker-Enfants-malades, AP-HP, National Reference Center for Cytomegalovirus, Paris, France, 2Hopital Antoine Beclere, APHP, Virologie, Clamart, France, 3Hopital Necker-Enfants malades, Maternite, Paris, France, 4Hopital de Poissy, Maternite, Poissy, France, 5Institut de Puericulture, Neonatalogie, Paris, France and 6Universite Paris-Descartes EA 36-20, Paris, France * Corresponding author
American Journal of Obstetrics and Gynecology | 2016
Marianne Leruez-Ville; J. Stirnemann; Yann Sellier; Tiffany Guilleminot; Anne Dejean; Jean-François Magny; Sophie Couderc; François Jacquemard; Yves Ville
Clinical Infectious Diseases | 2017
Marianne Leruez-Ville; Jean-François Magny; Sophie Couderc; Christine Pichon; Marine Parodi; Laurence Bussières; Tiffany Guilleminot; Idir Ghout; Y. Ville
BMC Pediatrics | 2017
Enora Laas; Nathalie Lelong; Pierre-Yves Ancel; Damien Bonnet; Lucile Houyel; Jean-François Magny; Thibaut Andrieu; François Goffinet; Babak Khoshnood
Journal of Clinical Virology | 2015
Marianne Leruez-Ville; I. Ghout; Jean-François Magny; S. Couderc; F. Jacquemard; Yves Ville
Archives De Pediatrie | 2009
Marianne Leruez-Ville; C. Vauloup-Fellous; S. Couderc; Sophie Parat; Salima Oucherif; C. Castel; Jean-François Magny
Ultrasound in Obstetrics & Gynecology | 2018
V. Faure-Bardon; J. Stirneman; N. Cornet; Jean-François Magny; M. Nicloux; Marianne Leruez-Ville; Y. Ville